|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
|
rs113488022
|
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorectal tumors and significantly associated to defective mismatch repair (MMR).
|
14668801 |
2003 |
|
rs113488022
|
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
In addition, a significant association between mismatch-repair (MMR) deficiency and the V599E mutation in colorectal tumors has been found.
|
14654916 |
2004 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
|
19001320 |
2008 |
|
rs113488022
|
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Rac1b overexpression and B-Raf(V600E) are significantly associated in primary colorectal tumors (P = .008) and colorectal cell lines.
|
18602919 |
2008 |
|
rs113488022
|
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.
|
19213871 |
2009 |
|
rs113488022
|
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
Secondly, considering the alternative possibility, we identified genes whose DNA hypermethylation was closely linked to BRAF(V600E) and CIMP in 235 primary colorectal tumors.
|
20027224 |
2009 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Clinical biomarkers in oncology: focus on colorectal cancer.
|
19537845 |
2009 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
|
20350999 |
2010 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
|
20413299 |
2010 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
|
21129611 |
2010 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
BRAF as a target for cancer therapy.
|
21426297 |
2011 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
|
21163703 |
2011 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
|
20857202 |
2011 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
|
22180495 |
2012 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
|
22448344 |
2012 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
|
22281684 |
2012 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
|
23549875 |
2013 |
|
rs113488022
|
|
Colorectal Neoplasms
|
|
0.790 |
GeneticVariation
|
BEFREE |
To verify the technical characteristics of the microarray system for the correct identification of the KRAS mutational status at the two hotspot codons 12 and 13 and of the BRAF(V600E) mutation in colorectal tumor, we selected 75 samples previously characterized by conventional and CO-amplification at Lower Denaturation temperature-PCR (COLD-PCR) followed by High Resolution Melting analysis and direct sequencing.
|
23536897 |
2013 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
|
23251002 |
2013 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
|
23845441 |
2013 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
|
23812671 |
2013 |
|
rs113488022
|
|
Colorectal Neoplasms
|
T |
0.790 |
CausalMutation
|
CLINVAR |
Our findings indicated that proteasome inhibition might represent a valuable targeting strategy in BRAF V600E-mutant colorectal tumors.
|
24107445 |
2013 |